Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Female Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm
Female Reproductive System Neoplasm

Subtype

Female Reproductive System Neoplasm

CI-CAN-00000885Explore in graph →

Non-malignant1,629 active trials11 approved drugs139 evidence items

NCIt: C3053
MeSH: D005833

Overview
Statistics
Survival
Genomics36
Variants & evidence139
Drugs44
Trials7170
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (324)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 276–300 of 324 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
· J Clin Oncol · 2015 · PMID 26324360 · validated civic_curation pubmed
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
· J Clin Invest · 2016 · PMID 27159395 · validated civic_curation pubmed
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
· Invest New Drugs · 2015 · PMID 26490654 · validated civic_curation pubmed
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.
· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed
Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.
· Cancer Chemother Pharmacol · 2009 · PMID 18607592 · validated civic_curation pubmed
A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
· Gynecol Oncol · 2006 · PMID 16487996

Showing 276–300 of 324 publications

← Previous
1
…
11
12
13
Next →

· validated civic_curation

A novel K-ras mutation in colorectal cancer. A case report and literature review.

· Anticancer Res · 2009 · PMID 19661358 · validated civic_curation pubmed

Targeted Treatment of a Rare Vaginal Sarcoma With an Anaplastic Lymphoma Kinase Inhibitor.

· Obstet Gynecol · 2016 · PMID 26942346 · validated civic_curation pubmed

Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report.

· Gynecol Oncol Rep · 2019 · PMID 30809568 · validated civic_curation pubmed

Somatic aberrations of mismatch repair genes as a cause of microsatellite-unstable cancers.

· J Pathol · 2014 · PMID 25111426 · validated civic_curation pubmed

EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.

· Front Med (Lausanne) · 2022 · PMID 35572973 · validated civic_curation pubmed

Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.

· Cancer Res · 2014 · PMID 24240700 · validated civic_curation pubmed

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines.

· Br J Cancer · 2014 · PMID 25010864 · validated civic_curation pubmed

Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.

· Carcinogenesis · 2013 · PMID 23764753 · validated civic_curation pubmed

Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.

· Clin Cancer Res · 2017 · PMID 27663592 · validated civic_curation pubmed

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

· Cancer Cell · 2003 · PMID 12559175 · validated civic_curation pubmed

LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin.

· Cancer Res · 2012 · PMID 22896685 · validated civic_curation pubmed

Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.

· Cancer Cell · 2015 · PMID 26096845 · validated civic_curation pubmed

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

· Cancer Cell · 2010 · PMID 20227043 · validated civic_curation pubmed

KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

· Cancer Res · 2015 · PMID 25968887 · validated civic_curation pubmed

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.

· Cancer Biol Ther · 2016 · PMID 26574622 · validated civic_curation pubmed

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.

· Cancer Res · 2008 · PMID 18757403 · validated civic_curation pubmed

Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.

· Clin Cancer Res · 2011 · PMID 21278246 · validated civic_curation pubmed

PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

· Clin Cancer Res · 2013 · PMID 23674493 · validated civic_curation pubmed